Shaan Dudani, M.B. Ch.B.1 • Horia Marginean, M.S., M.D.1 • Joanna Gotfrit, M.D.1 Patricia A. Tang, M.D.2 • Jose Gerard Monzon, M.D., Ph.D.2 • Kristopher Dennis, M.D., Ph.D.1 • Hagen F. Kennecke, M.D.3 • Erin D. Powell, M.D.4 • Sam Babak, M.D.2 • Winson
In patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation, baseline chronic kidney disease was associated with less use of adjuvant chemotherapy and decreased disease-free survival. Chronic kidney disease was not independently associated with neoadjuvant chemotherapy/radiotherapy completion rate, pathologic complete response, or overall survival. These data suggest that patients with locally advanced rectal cancer with chronic kidney disease may have distinct outcomes and, accordingly, the results of landmark clinical trials may not be generalizable to this population.